GIP and type 2 diabetes mellitus: Obesity and diabetes are well‐known risk factors for various cancers.[21] TZP, designed to act on both the GIP and GLP‐1 receptors, has recently emerged as a promising injectable drug for T2DM treatment and received FDA approval following successful clinical trials (SURPASS1/2/3/4 and 5, NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503).[5, 22] Beyond its strengths on T2DM observed in clinical practice, whether TZP, when used as an anti‐diabetic drug in diabetic patients, could benefit cancer therapeutics or increase the risk of cancer progression remains unexplored.